By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today said that it has licensed exclusive rights from Stanford University to several biomarkers that it intends to use in developing a molecular diagnostics test.

Abbott said that it intends to develop a test that can differentiate aggressive from nonaggressive prostate cancer, a currently unmet medical need.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.